GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (FRA:20D0) » Definitions » Cyclically Adjusted Book per Share

Cidara Therapeutics (FRA:20D0) Cyclically Adjusted Book per Share : €51.98 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Cidara Therapeutics's adjusted book value per share for the three months ended in Mar. 2025 was €10.734. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €51.98 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Cidara Therapeutics's average Cyclically Adjusted Book Growth Rate was 3.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2025-06-27), Cidara Therapeutics's current stock price is €41.80. Cidara Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €51.98. Cidara Therapeutics's Cyclically Adjusted PB Ratio of today is 0.80.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Cidara Therapeutics was 0.87. The lowest was 0.20. And the median was 0.29.


Cidara Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Cidara Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Cyclically Adjusted Book per Share Chart

Cidara Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 47.19 44.63

Cidara Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.95 42.64 46.17 44.63 51.98

Competitive Comparison of Cidara Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Cidara Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cidara Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cidara Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Cidara Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cidara Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=10.734/134.9266*134.9266
=10.734

Current CPI (Mar. 2025) = 134.9266.

Cidara Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 158.359 100.684 212.217
201509 146.495 100.392 196.890
201512 138.448 99.792 187.192
201603 123.382 100.470 165.696
201606 108.604 101.688 144.103
201609 94.624 101.861 125.340
201612 99.635 101.863 131.976
201703 84.583 102.862 110.949
201706 64.680 103.349 84.442
201709 50.333 104.136 65.216
201712 49.205 104.011 63.830
201803 38.630 105.290 49.504
201806 50.802 106.317 64.473
201809 43.179 106.507 54.701
201812 37.371 105.998 47.570
201903 29.143 107.251 36.663
201906 21.022 108.070 26.246
201909 26.944 108.329 33.559
201912 20.125 108.420 25.045
202003 23.987 108.902 29.719
202006 17.478 108.767 21.682
202009 11.420 109.815 14.031
202012 3.925 109.897 4.819
202103 0.658 111.754 0.794
202106 5.295 114.631 6.232
202109 -0.397 115.734 -0.463
202112 5.627 117.630 6.454
202203 1.304 121.301 1.450
202206 -2.175 125.017 -2.347
202209 2.573 125.227 2.772
202212 -3.761 125.222 -4.052
202303 5.569 127.348 5.900
202306 3.152 128.729 3.304
202309 1.666 129.860 1.731
202312 -1.662 129.419 -1.733
202403 -3.586 131.776 -3.672
202406 26.623 132.554 27.100
202409 14.784 133.029 14.995
202412 14.247 133.157 14.436
202503 10.734 134.927 10.734

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Cidara Therapeutics  (FRA:20D0) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cidara Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=41.80/51.98
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Cidara Therapeutics was 0.87. The lowest was 0.20. And the median was 0.29.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Cidara Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cidara Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics Headlines

No Headlines